Clinical Trials Logo

Melanoma clinical trials

View clinical trials related to Melanoma.

Filter by:

NCT ID: NCT02883933 Completed - Melanoma Clinical Trials

Clinical and Histological Features of Head and Neck Melanoma

head neck-mel
Start date: January 2004
Phase: N/A
Study type: Observational

The worldwide incidence of cutaneous melanoma has been increasing for the last 30 years in western populations. Among all melanomas, those located on the head and neck are more frequent than expected regarding the surface of this anatomical area, occur in older subjects than melanomas at other sites and have a worse prognosis than melanomas at other sites. The question whether head and neck melanomas could be a distinct entity has been debated.

NCT ID: NCT02875652 Completed - Choroidal Melanoma Clinical Trials

Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU)

ctDNA MU
Start date: March 21, 2013
Phase: N/A
Study type: Interventional

Quantification and follow-up during 3 years of circulating tumoral DNA in patients with choroidal melanoma

NCT ID: NCT02875132 Completed - Clinical trials for Acral Lentiginous Melanoma

Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma

Start date: February 15, 2017
Phase: Phase 2
Study type: Interventional

To determine the Overall Response Rate (ORR), as defined as rate of complete response (CR) and partial response (PR) as per RECIST 1.1 in biological treatment-naïve patients with acral lentiginous melanoma treated with pembrolizumab

NCT ID: NCT02872259 Completed - Melanoma Clinical Trials

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

Start date: February 13, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to assess the safety and efficacy of BGB324 given together with standard treatment, pembrolizumab or dabrafenib and trametinib, compared to standard treatment alone,

NCT ID: NCT02862743 Completed - Metastatic Melanoma Clinical Trials

Molecular Characterization of Advanced Stage Melanoma by Blood Sampling

MELCIRC
Start date: January 14, 2016
Phase: N/A
Study type: Interventional

Analysis of somatic mutations in tumors is currently indicated for daily practice in all metastatic melanoma. Actually, this research is limited to the mutation of three biomarkers validated by the l'Institut National du CAncer (INCA): BRAF, NRAS and CKIT. Moreover, in some cases it requires invasive biopsies. In this context, molecular characterization of a tumor material flowing (circulating tumor DNA and / or circulating tumor cells) could afford to benefit patients in the best conditions of current targeted therapies and future.

NCT ID: NCT02858869 Completed - Metastatic Melanoma Clinical Trials

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Start date: October 4, 2016
Phase: Phase 1
Study type: Interventional

This pilot trial studies the side effects of giving pembrolizumab together with stereotactic radiosurgery to treat patients with melanoma or non-small cell lung cancer that has spread to the brain. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Giving pembrolizumab together with stereotactic radiosurgery may be a better treatment for patients with melanoma or non-small cell lung cancer that has spread to the brain.

NCT ID: NCT02857569 Completed - Clinical trials for Stage III/IV Melanoma

A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma

NIVIPIT
Start date: December 5, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The study aims to evaluate the 6 month-treatment tolerance defined as the immune related grade 3-4 adverse event-free survival of the combination therapy IT ipilimumab + IV nivolumab. The IV ipilimumab + IV nivolumab (same doses than in Phase I) arm will be used as an internal control to interpret the results obtained in the IT ipilimumab arm.

NCT ID: NCT02857374 Completed - Clinical trials for Stage IIIC Skin Melanoma

Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy

Start date: November 3, 2016
Phase: N/A
Study type: Interventional

This pilot clinical trial studies intravital microscopy in identifying tumor vessels in patients with stage IB-IIIC melanoma undergoing sentinel lymph node biopsy. By examining sentinel lymph nodes through intravital microscopy before they are removed, doctors may learn specific information regarding how melanoma may spread to lymph nodes and other sites of the body.

NCT ID: NCT02854657 Completed - Melanoma Clinical Trials

Teaching Skin Self -Examination to Melanoma Patients and Their Skin Check Partners

PSW
Start date: May 2016
Phase: N/A
Study type: Interventional

The proposed study is a continuation of a research program (STU00017005: Interventions to teach melanoma patients skin self-examination) designed to increase early detection of melanomas before they metastasize. In 2015, approximately 73,870 individuals in the U.S. will be diagnosed with invasive melanoma and about 9,940 will die from the disease. During 2002-2011, melanoma incidence increased at an average annual rate of 1.6% for men and 1.5% for women. People with a history of melanoma have a 10 times greater risk of developing a second primary melanoma relative to the general population. Early detection with surgical excision at an earlier stage when treatment is usually more effective is the only proven curative strategy. Relationship factors to help sustain skin self-examination will also be evaluated. The study has been amended to include an administrative supplement, which builds upon the pilot research completed during the summer of 2017 that measured the efficacy of two wearable UV sensors (Shade and Wearifi) and a survey assessing sun protection along with the quality of life. See Detailed Description for a description of amendment addition. This research was expanded to distance (remote) learning provided by mailing the same workbook used in the in-office training.

NCT ID: NCT02854124 Completed - Melanoma Clinical Trials

Tracing Dissemination of Melanoma Cells in Healthy Tissues

DISSEMELA
Start date: October 12, 2017
Phase:
Study type: Observational

The objective of this project is to evaluate the presence of melanoma quiescent or initiating clonal cells in peritumoral healthy tissue displaying the same molecular signature than those of the tumor/metastasis and to correlate this presence to the prognostic value.